Naoki Iwanaga

Dr. Naoki Iwanaga

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2021 in Science Immunology
Verified
Journal Article
Closed access
NINaoki Iwanaga
Naoki Iwanaga
KCKong Chen
Kong Chen
HYHaoran Yang
Haoran Yang
SLShiping Lu
Shiping Lu
JHJoseph P. Hoffmann
Joseph P. Hoffmann
JKJay Kolls
Jay Kolls
A subunit mucosal vaccine conferred protection against heterologous Klebsiella pneumoniae strains, via IL-17R signaling in lung fibroblasts.

1 January 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MTMasato Tashiro
Masato Tashiro
KIKoichi Izumikawa
Koichi Izumikawa
AMAsuka Minematsu
Asuka Minematsu
KHKatsuji Hirano
Katsuji Hirano
NINaoki Iwanaga
Naoki Iwanaga
SKShigeru Kohno
Shigeru Kohno
We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively.

27 September 2018 in Immunology
Verified
Journal Article
Open access
PDF file
NINaoki Iwanaga
Naoki Iwanaga
JKJay Kolls
Jay Kolls
Summary: Interleukin‐17 (IL‐17)‐producing cells play a critical role in mucosal immunity including the respiratory tract. This review will highlight recent advances in our understanding of these cells in mucosal immunity in the lung as well as their potential pathogenic roles in respiratory diseases. The IL‐17‐producing cells include γδ T cells, natural killer cells, group 3 innate lymphoid cells, and T helper type 17 (Th17) cells. There have been recent advances in our understanding of these cell populations in the lung as well as emerging data on how these cells are regulated in the lung. Moreover, Th17 cells may be a key component of tissue‐resident memory cells that may be acquired over time or elicited by mucosal immunization that provides the host with enhanced immunity against certain pathogens.

16 October 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
TKToshiki Kajihara
Toshiki Kajihara
SNShigeki Nakamura
Shigeki Nakamura
NINaoki Iwanaga
Naoki Iwanaga
KOKazuhiro Oshima
Kazuhiro Oshima
TTTakahiro Takazono
Takahiro Takazono
SKShigeru Kohno
Shigeru Kohno
Enterococcus spp. are particularly important etiological agents of nosocomial infections. However, the clinical characteristics of and risk factors for enterococcal infections in clinical settings are poorly understood. The sample included patients with Enterococcus spp. infections detected from clinical samples at Nagasaki University Hospital between 2010 and 2011 and patients with enterococcal colonization (control patients). In this retrospective study, the risk factors for enterococcal infections were analyzed by comparing infected and control patients via multivariate logistic regression. A total of 182 infected (mean age, 64.6 ± 18.2 years; 114 men) and 358 control patients (patients with enterococcal colonization) (mean age, 61.6 ± 22.4 years; 183 men) were included. Enterococcal infections were classified as intraperitoneal (n = 87), urinary tract (n = 28), or bloodstream (n = 20) infections. Cancer and hematological malignancies were the most common comorbidities in enterococcal infections. Carbapenem and vancomycin were administered to 43.8 % and 57.9 % of patients infected with Enterococcus faecalis and Enterococcus faecium, respectively. No vancomycin-resistant enterococci were isolated. Multivariate analysis identified abdominal surgery (odds ratio [OR], 2.233; 95 % confidence interval [CI], 1.529–3.261; p ≤ 0.001), structural abnormalities of the urinary tract (OR, 2.086; 95 % CI, 1.088–4.000; p = 0.027), male sex (OR, 1.504; 95 % CI, 1.032–2.190; p = 0.033), and hypoalbuminemia (OR, 0.731; 95 % CI, 0.555–0.963; p = 0.026) as independent risk factors for enterococcal infections. Multivariate analysis showed abdominal surgery (OR, 2.263; 95 % CI, 1.464–3.498; p ≤ 0.001), structural abnormalities of the urinary tract (OR, 2.634; 95 % CI, 1.194–5.362; p = 0.008), and hypoalbuminemia (OR, 0.668; 95 % CI, 0.490–0.911; p = 0.011) were independent risk factors for E. faecalis infection. Finally, immunosuppressive agent use (OR, 3.837; 95 % CI, 1.397–10.541; p = 0.009) and in situ device use (OR, 3.807; 95 % CI, 1.180–12.276; p = 0.025) were independent risk factors for E. faecium infection. These findings might inform early initiation of antimicrobial agents to improve clinical success.

20 December 2021 in iScience
Verified
Journal Article
Open access
NINaoki Iwanaga
Naoki Iwanaga
LCLaura Cooper
Laura Cooper
Lijun RongLijun Rong
Lijun Rong
NMNicholas J. Maness
Nicholas J. Maness
BBBrandon J Beddingfield
Brandon J Beddingfield
JKJay Kolls
Jay Kolls
SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2. A mutation in the catalytic domain of ACE2, MDR504, significantly increased binding to SARS-CoV-2 spike protein, as well as to a spike variant, in vitro with more potent viral neutralization in plaque assays. Parental administration of the protein showed stable serum concentrations with excellent bioavailability in the epithelial lining fluid of the lung, and ameliorated lung SARS-CoV-2 infection in vivo. These data support that the MDR504 hACE2-Fc is an excellent candidate for treatment or prophylaxis of COVID-19 and potentially emerging variants.

3 July 2025 in Respiratory Investigation
Verified
Journal Article
Open access
HMHiroshi Mukae
Hiroshi Mukae
NINaoki Iwanaga
Naoki Iwanaga
NHNobuyuki Horita
Nobuyuki Horita
KKKosaku Komiya
Kosaku Komiya
TMTakaya Maruyama
Takaya Maruyama
NMNaoyuki Miyashita
Naoyuki Miyashita
The Japanese Respiratory Society published the Adult Pneumonia Practice Guidelines 2024 in April 2024. In Japan, a super-aged society, the disease burden of pneumonia is significant and is expected to grow in the future. Given this historical context, the most important themes in this revision of the guidelines include the appropriate use of antibiotics and measures against pneumonia in older adults. A large portion of these cases involves aspiration pneumonia, making it challenging to achieve fundamental improvement with antibiotic treatment alone and necessitating a comprehensive approach. Preventing pneumonia and maintaining physical function are essential points for improving the prognosis of pneumonia in older adults, with an emphasis on promoting vaccination, rehabilitation, and oral care. The treatment of Nursing and Healthcare-Associated Pneumonia (NHCAP), a Japan-specific category adapted from the ATS/IDSA's HCAP guidelines, has been extensively reviewed. Despite international moves away from HCAP due to concerns about the overuse of broad-spectrum antibiotics, Japan has chosen to retain NHCAP for treating pneumonia in older adults while implementing stricter controls on antibiotic use to promote antimicrobial stewardship. In cases of repeated aspiration pneumonia or in situations where the patient is in a terminal state of age-related decline or the final stage of comorbidities, all pneumonia patients are recommended to undergo a background assessment, occasionally prioritizing palliative care and respecting the patient's outlook on life. The importance of advanced care planning has also been highlighted to underscore the need for interdisciplinary collaboration with medical doctors and other healthcare professionals.